Prostate Cancer

FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer

On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient...

 

Breast Cancer
Genomics/Genetics

Somatic Driver Alterations and Distant Recurrence in Postmenopausal Early Breast Cancer Patients Receiving Endocrine Therapy

In an analysis from the BIG 1-98 trial reported in JAMA Oncology, Luen et al found that 11q13and 8p11 amplifications were associated with an increased risk...

 

Head and Neck Cancer

Pazopanib Plus Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

As reported in The Lancet Oncology by Adkins et al, the addition of the angiogenesis inhibitor pazopanib to cetuximab in a phase Ib and expansion cohort...

 


Advertisement
Skin Cancer
CNS Cancers

First-Line Treatment With Checkpoint Inhibitors in Patients With Melanoma Brain Metastases

An analysis of newly diagnosed patients with cutaneous melanoma brain metastases treated with checkpoint blockade immunotherapy...

 

Issues in Oncology

American Cancer Society Outlines Blueprint for Cancer Control in the 21st Century

The American Cancer Society (ACS) is outlining its vision for cancer control in the decades ahead in a series of articles...

 


More Top Stories

Prostate Cancer

Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men

New Fellows Begin 2018–2019 ASCO Health Policy Fellowship Program

TREVOR ROYCE, MS, MD, MPH, and Sheetal Kircher, MD, are the 2018–2019 ASCO Health Policy Fellows. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge, skills, and experience necessary to shape regulatory and legislative policies that directly ...

Advertisement

Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma

In a study reported in JAMA Oncology, Carlo et al found a high prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma (RCC). Study Details In this cohort study, conducted between October 2015 and July 2017, 254 of 267 patients with advanced...

Lymphoma

Jeremy S. Abramson, MD, on Non-Hodgkin Lymphoma: Results From the TRANSCEND NHL 001 Trial

Today’s Breakthroughs Require Year-Round Support

PROMISING BREAKTHROUGHS in cancer care don’t just happen overnight; they result after years of hard work by the brightest minds in cancer research. Yet many are unaware of the vast resources necessary to fuel cutting-edge research projects. Increasing awareness around this issue is vital to...

Solid Tumors
Lung Cancer
Issues in Oncology
Supportive Care

Racial/Ethnic Disparities in End-of-Life Care Among Patients With Lung Cancer

Significant disparities in the quality of end-of-life lung cancer care were found among racial/ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end of life as compared with non-Hispanic whites. These findings were published by Siddharth...

American Cancer Society Outlines Blueprint for Cancer Control in the 21st Century

The American Cancer Society (ACS) is outlining its vision for cancer control in the decades ahead in a series of articles that began publishing in early July in CA: A Cancer Journal for Clinicians. The series of articles forms the basis of a national cancer control plan, with a blueprint...

Breast Cancer

Joseph A. Sparano, MD, on Breast Cancer: Results of the TAILORx Trial

Issues in Oncology
Survivorship

Raising Awareness of the Financial Impact of Cancer on Young Adult Survivors

GUEST EDITOR Adolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon Hayes-Lattin, MD, FACP, Associate Professor of Medicine and...

Advertisement

First-Line Treatment With Checkpoint Inhibitors in Patients With Melanoma Brain Metastases

  An analysis of newly diagnosed patients with cutaneous melanoma brain metastases treated with checkpoint blockade immunotherapy has found the treatment was associated with an increase in median overall survival of 12.4 months compared with 5.2 months—a 1.4-fold improvement. The...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.